Directed Evolution of Novel AAV Vectors for Clinical Gene Therapy

Explore the cutting-edge field of gene therapy through this 48-minute webinar presented by Dr. David Schaffer, focusing on the directed evolution of adeno-associated virus (AAV) vectors for clinical applications. Learn how molecular and cellular engineering approaches are revolutionizing gene therapy by addressing the fundamental limitations of natural viral vectors, including limited delivery efficiency, pre-existing antibodies, suboptimal biodistribution, and inability to target specific cells. Discover the innovative directed evolution methodology that involves iterative genetic diversification of viral genomes and functional selection to create highly optimized, next-generation AAV variants capable of efficient and targeted delivery to any cell or tissue target. Understand the comprehensive range of genetic diversification approaches from fully random methods like error-prone PCR to computationally guided techniques using machine learning to generate large libraries of approximately 10^9 variants. Examine real-world applications and results from both animal models and six human clinical trials that demonstrate the effectiveness of these engineered AAV variants in therapeutic gene delivery. Gain insights into how these technologies are advancing treatments for diseases of the nervous system and other tissues, with particular emphasis on neurodegenerative diseases and stem cell-based therapies. Access PACE credits upon completion and connect with the broader scientific community through Labroots' comprehensive educational platform.